ESR1 and breast carcinoma: Beyond the first proof-of-principle efficacy of adjuvant pharmacological hPRL pathway targeting on residual lung metastases of human ER+ breast cancer documented here, future studies will determine the broader usefulness of the NSG-Pro mouse in development and preclinical assessment of novel adjuvant therapies for disseminated disease.